The effect of vitamin D deficiency treatment on dyspnea severity in patients with COPD

Comparison of the effect of vitamin D and placebo on clinical and spirometric indices in patients with chronic obstructive pulmonary disease (COPD).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017042919554N12

Enrollment

Registered

2017-10-27

Start date

2016-07-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease. Emphysema -Other specified chronic obstructive pulmonary disease-Chronic obstructive pulmonary disease, unspecified- -

Interventions

Intervention 1: Intervention group: 50000 IU Pearl vitamin D every week and 500mg calcium-D tablet daily (for three month). Intervention 2: Control group: Perl placebo every week and calcium-D 500 mg

Treatment - Drugs

Placebo

Intervention group: 50000 IU Pearl vitamin D every week and 500mg calcium-D tablet daily (for three month)

Control group: Perl placebo every week and calcium-D 500 mg tablets daily (for three months)

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Outpatients suffering from COPD who haven’t had COPD exacerbation in last 2 weeks; serum vitamin D level less than 30 ng / dl; written consent for participating in the study. Exclusion Criteria: liver problems (LFT equal to or more than 2 times more than normal); renal failure (GFR<60); Granulomatous diseases (including tuberculosis, sarcoidosis); malnutrition; malabsorption (including IBD and Celiac); any types of cancer; parathyroid disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Forced expiratory volume (FEV1). Timepoint: Before the intervention and three months after the end of intervention. Method of measurement: spirometery.;Forced expiratory volume 1/ Forced vital capacity(FEV1/FVC). Timepoint: Before the intervention and three months after the end of intervention. Method of measurement: Spirometry.	—

Secondary

Measure	Time frame
Severity of Dyspnea. Timepoint: Before the intervention and three months after the end of intervention. Method of measurement: MRC Dyspnoea Scale.;Weight. Timepoint: Before the intervention and three months after the end of intervention. Method of measurement: Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Jameshorani

Zanjan University of Medical Sciences

ZMDRC@zums.ac.ir+98 24 3377 0723

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026